Renal anaemia and EPO hyporesponsiveness associated with vitamin D deficiency: The potential role of inflammation

Nephrology Dialysis Transplantation

Volumn 28, Issue 7, 2013, Pages 1672-1679

  Icardi, Andrea ^a   Paoletti, Ernesto ^b   De Nicola, Luca ^c   Mazzaferro, Sandro ^d   Russo, Roberto ^e   Cozzolino, Mario ^f  

^a La Colletta and Villa Scassi Hospitals ASL 3   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e UNIVERSITY OF BARI   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

Author keywords

CKD anaemia; EPO resistance; Inflammation; Vitamin D deficiency; Vitamin D supplementation

Indexed keywords

25 HYDROXYVITAMIN D; ALFACALCIDOL; CALCITRIOL; ERYTHROPOIETIN; VITAMIN D; VITAMIN D DERIVATIVE;

ANEMIA; ANTIINFLAMMATORY ACTIVITY; BINDING AFFINITY; BINDING SITE; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; DISEASE CONTROL; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG PROTEIN BINDING; ERYTHROPOIESIS; HUMAN; INFLAMMATION; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; RENAL ANEMIA; REVIEW; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

CKD ANAEMIA; EPO RESISTANCE; INFLAMMATION; VITAMIN D DEFICIENCY; VITAMIN D SUPPLEMENTATION;

ANEMIA; ANIMALS; CYTOKINES; ERYTHROPOIETIN; HUMANS; INFLAMMATION; RENAL INSUFFICIENCY, CHRONIC; VITAMIN D DEFICIENCY;

EID: 84884507965     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft021     Document Type: Review

References (88)

1. Nangaku M, Eckardt KU. Pathogenesis of renal anemia. Semin Nephrol 2006; 26: 261-268
2. Costa E, Rocha S, Rocha-Pereira P et al. Neutrophil activation and resistance to recombinant human erythropoietin therapy in hemodialysis patients. Am J Nephrol 2008; 28: 935-940
3. Locatelli F, Aljama P, Bárány P et al. European Best Practice Guidelines Working Group. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19(Suppl. 2): ii1-ii47
4. Szczech LA, Barnhart HX, Inrig JK et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 2008; 74: 791-798
5. Solomon SD, Uno H, Lewis EF et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 2010; 363: 1146-1155
6. Minutolo R, Conte G, Cianciaruso B et al. Hyporesponsiveness to erythropoiesis-stimulating agents and renal survival in nondialysis CKD patients. Nephrol Dial Transplant 2012. (Epub ahead of print)
7. Kilpatrick RD, Critchlow CW, Fishbane S et al. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: 1077-1083
8. Bamgbola OF. Pattern of resistance to erythropoietin-stimulating agents in chronic kidney disease. Kidney Int 2011; 80: 464-474
9. Patel NM, Gutiérrez OM, Andress DL et al. Vitamin D deficiency and anemia in early chronic kidney disease. Kidney Int 2010; 77: 715-720
10. Perlstein TS, Pande R, Berliner N et al. Prevalence of 25-hydroxyvitamin D deficiency in subgroups of elderly persons with anemia: association with anemia of inflammation. Blood 2011; 117: 2800-2806
11. Kiss Z, Ambrus C, Almasi C et al. Serum 25(OH)-cholecalciferol concentration is associated with hemoglobin level and erythropoietin resistance in patients on maintenance hemodialysis. Nephron Clin Pract 2011; 117: c373-c378
12. Baeke F, Takiishi T, Korf H et al. Vitamin D: modulator of the immune system. Curr Opin Pharmacol 2010; 10: 482-496
13. Alborzi P, Patel NA, Peterson C et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 2008; 52: 249-255
14. Stubbs JR, Idiculla A, Slusser J. Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD. J Am Soc Nephrol 2010; 21: 353-361
15. Dao M, Verfaillie CM. Chapter 18. In: Hoffman R, Benz EJ, Furie B et al. (eds). Hematology. Basic principles and Practice. 4th edn, Elsevier Churchill Livingstone, 2005
16. Koury MJ, Mahmud N, Rhodes MM. Part II Section 1 Hematopoiesis Chapter 5. In: Greer JP, Foerster J, Rodgers GM et al. (eds). Wintrobe's Clinical Hematology. Vol. 1, 12th edn, Lippincott Williams &Wilkins, 2009
17. Davis SL, Littlewood TJ. The investigation and treatment of secondary anaemia. Blood Rev 2012; 26: 65-71
18. Besarab A, Coyne DW. Iron supplementation to treat anemia in patients with chronic kidney disease. Nat Rev Nephrol 2010; 6: 699-710
19. Babitt JL, Lin HY. Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. Am J Kidney Dis 2010; 55: 726-741
20. Uehata T, Tomosugi N, Shoji T et al. Serum hepcidin-25 levels and anemia in non-dialysis chronic kidney disease patients: a cross-sectional study. Nephrol Dial Transplant 2012; 27: 1076-1083
21. Boxer M, Ellman L, Geller R et al. Anemia in primary hyperparathyroidism. Arch Intern Med 1977; 137: 588-593
22. Di Iorio BR, Minutolo R, De Nicola L et al. Supplemented very low protein diet ameliorates responsiveness to erythropoietin in chronic renal failure. Kidney Int 2003; 64: 1822-1828
23. Brancaccio D, Cozzolino M, Gallieni M. Hyperparathyroidism and anemia in uremic subjects: a combined therapeutic approach. J Am Soc Nephrol 2004; 15(Suppl. 1): S21-S24
24. Hörl WH. The clinical consequences of secondary hyperparathyroidism: focus on clinical outcomes. Nephrol Dial Transplant 2004; 19(Suppl. 5): V2-V8. 2010 Apr;55:726-41
25. Gaweda AE, Goldsmith LJ, Brier ME et al. Iron, inflammation, dialysis adequacy, nutritional status, and hyperparathyroidism modify erythropoietic response. Clin J Am Soc Nephrol 2010; 5: 576-581
26. Rao DS, Shih MS, Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med 1993; 328: 171-175
27. Lin CL, Hung CC, Yang CT et al. Improved anemia and reduced erythropoietin need by medical or surgical intervention of secondary hyperparathyroidism in hemodialysis patients. Ren Fail 2004; 26: 289-295
28. Capuano A, Serio V, Pota A et al. Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients. J Nephrol 2009; 22: 59-68
29. Bowry SK, Gatti E. Impact of hemodialysis therapy on anemia of chronic kidney disease: the potential mechanisms. Blood Purif 2011; 32: 210-219
30. Kalantar-Zadeh K, Lee GH, Miller JE et al. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. Am J Kidney Dis 2009; 53: 823-834
31. Sahin G, Kirli I, Sirmagul B et al. Loss via peritoneal fluid as a factor for low 25(OH)D3 level in peritoneal dialysis patients. Int Urol Nephrol 2009; 41: 989-996
32. Dusso A, González EA, Martin KJ. Vitamin D in chronic kidney disease. Best Pract Res Clin Endocrinol Metab 2011; 25: 647-655
33. Andress DL. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int 2006; 69: 33-43
34. Sezer S, Tutal E, Bilgic A et al. Possible influence of vitamin D receptor gene polymorphisms on recombinant human erythropoietin requirements in dialysis patients. Transplant Proc 2007; 39: 40-44
35. Kendrick J, Targher G, Smits G et al. 25-Hydroxyvitamin D deficiency and inflammation and their association with hemoglobin levels in chronic kidney disease. Am J Nephrol 2009; 30: 64-72
36. Carvalho C, Isakova T, Collerone G et al. Hepcidin and disordered mineral metabolism in chronic kidney disease. Clin Nephrol 2011; 76: 90-98
37. Albitar S, Genin M, Fen-Chong M et al. High-dose alfacalcidol improves anemia in patients on hemodialysis. Nephrol Dial Transplant 1997; 12: 514-518
38. Goicoechea M, Vazquez MI, Ruiz MA et al. Intravenous calcitriol improves anaemia and reduces the need for erythropoietin in haemodialysis patients. Nephron 1998; 78: 23-27
39. Aucella F, Scalzulli RP, Gatta G et al. Calcitriol increases burstforming unit-erythroid proliferation in chronic renal failure. A synergistic effect with r-HuEpo. Nephron Clin Pract 2003; 95: c121-c127
40. Moorthi RN, Kandula P, Moe SM. Optimal vitamin D, calcitriol, and vitamin D analog replacement in chronic kidney disease: to D or not to D: that is the question. Curr Opin Nephrol Hypertens 2011; 20: 354-359. Review
41. Kumar VA, Kujubu DA, Sim JJ et al. Vitamin D supplementation and recombinant human erythropoietin utilization in vitamin Ddeficient hemodialysis patients. J Nephrol 2011; 24: 98-105
42. Mascia S, Garofalo C, Donnarumma G et al. Role of paracalcitol in the management of non-dialysis CKD: state of art and... Unmet needs. G Ital Nefrol 2010; 27: 616-628 Italian
43. Battistella M, Richardson RM, Bargman JM et al. Improved parathyroid hormone control by cinacalcet is associated with reduction in darbepoetin requirement in patients with end-stage renal disease. Clin Nephrol 2011; 76: 99-103
44. Fusaro M, D'Angelo A, Naso A et al. Treatment with calcimimetic (cinacalcet) alters epoetin dosage requirements in dialysis patients: preliminary report. Ren Fail 2011; 33: 732-735
45. Sola L, De Souza N, Sans A et al. Could severe 25 vitamin D deficiency be a risk factor for anemia in chronic kidney disease patients? Word Cong Nephrol 2011; [MO251]
46. Norman AW. Minireview: vitamin D receptor: new assignments for an already busy receptor. Endocrinology 2006; 147: 5542-5548
47. Sim JJ, Lac PT, Liu IL et al. Vitamin D deficiency and anemia: a cross-sectional study. Ann Hematol 2010; 89: 447-452
48. Devaraj S, Yun JM, Duncan-Staley CR et al. Low vitamin D levels correlate with the proinflammatory state in type 1 diabetic subjects with and without microvascular complications. Am J Clin Pathol 2011; 135: 429-433
49. Kalkwarf HJ, Denburg MR, Strife CF et al. Vitamin D deficiency is common in children and adolescents with chronic kidney disease. Kidney Int 2012; 81: 690-697
50. Yabu JM, Winkelmayer WC. Posttransplantation anemia: mechanisms and management. Clin J Am Soc Nephrol 2011; 6: 1794-1801.
51. Bárány P. Inflammation, serum C-reactive protein, and erythropoietin resistance. Nephrol Dial Transplant 2001; 16: 224-227
52. Gunnell J, Yeun JY, Depner TA et al. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 1999; 33: 63-72
53. Del Vecchio L, Pozzoni P, Andrulli S et al. Inflammation and resistance to treatment with recombinant human erythropoietin. J Ren Nutr 2005; 15: 137-141
54. Rathaus M. C-reactive protein in the assessment of iron status in patients on hemodialysis. G Ital Nefrol 2009; 26: 338-346 Italian
55. Kalantar-Zadeh K, McAllister CJ, Lehn RS et al. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis 2003; 42: 761-773
56. Carrero JJ, Axelsson J, Snaedal-Jonsdottir S et al. Low hemoglobin in prevalent HD patients is associated with higher inflammatory status: impact of variations in the gene encoding for interleukin-6. Am Soc Nephrol Congress 2006; [SA-PO30]
57. Shinzato T, Abe K, Furusu A et al. Serum pro-hepcidin level and iron homeostasis in Japanese dialysis patients with erythropoietin (EPO)-resistant anemia. Med Sci Monit 2008; 14: CR431-CR437
58. Rambod M, Kovesdy CP, Kalantar-Zadeh K. Combined high serum ferritin and low iron saturation in hemodialysis patients: the role of inflammation. Clin J Am Soc Nephrol 2008; 3: 1691-1701
59. Malyszko J, Malyszko JS, Mysliwiec M. Hyporesponsiveness to erythropoietin therapy in hemodialyzed patients: potential role of prohepcidin, hepcidin, and inflammation. Ren Fail 2009; 31: 544-548
60. Cooper AC, Mikhail A, Lethbridge MW et al. Increased expression of erythropoiesis inhibiting cytokines (IFN-gamma, TNF-alpha, IL-10, and IL-13) by T cells in patients exhibiting a poor response to erythropoietin therapy. J Am Soc Nephrol 2003; 14: 1776-1784
61. Kanbay M, Perazella MA, Kasapoglu B et al. Erythropoiesis stimulatory agent-resistant anemia in dialysis patients: review of causes and management. Blood Purif 2010; 29: 1-12
62. Faquin WC, Schneider TJ, Goldberg MA. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 1992; 79: 1987-1994
63. Nemeth E, Rivera S, Gabayan V et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004; 113: 1271-1276
64. Yilmaz MI, Solak Y, Covic A et al. Renal anemia of inflammation: the name is self-explanatory. Blood Purif 2011; 32: 220-225
65. Beaumont C, Karim Z. Iron metabolism: State of the art. Rev Med Interne 2013; 34: 17-25
66. Maruyama Y, Yokoyama K, Yamamoto H et al. Do serum hepcidin- 25 levels correlate with oxidative stress in patients with chronic kidney disease not receiving dialysis? Clin Nephrol 2012; 78: 281-286
67. Okonko DO, Marley SB, Anker SD et al. Suppression of erythropoiesis in patients with chronic heart failure and anaemia of unknown origin: evidence of an immune basis. Int J Cardiol 2011 [Epub ahead of print] PubMed PMID: 22192286
68. Cooper A, Mikhail A, Lethbridge MW et al. Pentoxifylline improves hemoglobin levels in patients with erythropoietinresistant anemia in renal failure. J Am Soc Nephrol 2004; 15: 1877-1882
69. Ferrari P, Mallon D, Trinder D et al. Pentoxifylline improves haemoglobin and interleukin-6 levels in chronic kidney disease. Nephrology (Carlton) 2010; 15: 344-349
70. Genovese MC, McKay JD, Nasonov EL et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to diseasemodifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008; 58: 2968-2980
71. Song SN, Tomosugi N, Kawabata H et al. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. Blood 2010; 116: 3627-3634
72. Arabul M, Gullulu M, Yilmaz Y et al. Effect of fluvastatin on serum prohepcidin levels in patients with end-stage renal disease. Clin Biochem 2008; 41: 1055-1058
73. Suassuna PG, Bastos MG. Intermittent doses of statin in hemodialysis patients with spontaneous low LDL cholesterol levels. Arq Bras Cardiol 2008; 90: 104-111
74. Movilli E, Camerini C, Gaggia P et al. Switch from Low Flux Hemodialysis to post dilutional on-line hemodiafiltration: effects on inflammation and recombinant human erythropoietin dose in uraemic patients. Am Soc Nephrol Congress 2009; [SA-PO2437]
75. Panichi V, Rosati A, Paoletti S et al. A vitamin E-coated polysulfone membrane reduces serum levels of inflammatory markers and resistance to erythropoietin-stimulating agents in hemodialysis patients: results of a randomized cross-over multicenter trial. Blood Purif 2011; 32: 7-14
76. Borges MC, Martini LA, Rogero MM. Current perspectives on vitamin D, immune system, and chronic diseases. Nutrition 2011; 27: 399-404
77. Tan X, Wen X, Liu Y. Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NFkappa B signaling. J Am Soc Nephrol 2008; 19: 1741-1752
78. Eleftheriadis T, Antoniadi G, Liakopoulos V et al. Paricalcitol reduces basal and lipopolysaccharide-induced (LPS) TNF-alpha and IL-8 production by human peripheral blood mononuclear cells. Int Urol Nephrol 2010; 42: 181-185
79. Guerrero F, Montes de Oca A, Aguilera-Tejero E et al. The effect of vitamin D derivatives on vascular calcification associated with inflammation. Nephrol Dial Transplant 2012; 27: 2206-2212
80. Kuntsevich V, Thijssen S, Kitzler T et al. Impact of paricalcitol administration on cytokine induction during hemodialysis. Am Soc Nephrol Congress 2009; [SA-PO2611]
81. Schleithoff SS, Zittermann A, Tenderich G et al. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 2006; 83: 754-759
82. Bucharles S, Barberato SH, Stinghen AE et al. Impact of cholecalciferol treatment on biomarkers of inflammation and myocardial structure in hemodialysis patients without hyperparathyroidism. J Ren Nutr 2012; 22: 284-291
83. Thomas MC, Cooper ME. Into the light? Diabetic nephropathy and vitamin D. Lancet 2010; 376: 1521-1522
84. Ganji V, Zhang X, Shaikh N et al. Serum 25-hydroxyvitamin D concentrations are associated with prevalence of metabolic syndrome and various cardiometabolic risk factors in US children and adolescents based on assay-adjusted serum 25-hydroxyvitamin D data from NHANES 2001-2006. Am J Clin Nutr 2011; 94: 225-233
85. Chagas CE, Borges MC, Martini LA et al. Focus on vitamin D, inflammation and type 2 diabetes. Nutrients 2012; 4: 52-67. (Epub 2012) Jan 20. Review
86. de Zeeuw D, Agarwal R, Amdahl M et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010; 376: 1543-1551
87. Marckmann P, Agerskov H, Thineshkumar S et al. Randomized controlled trial of cholecalciferol supplementation in chronic kidney disease patients with hypovitaminosis D. Nephrol Dial Transplant 2012; 27: 3523-3531
88. Matias PJ, Jorge C, Ferreira C et al. Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters. Clin J Am Soc Nephrol 2010; 5: 905-911